ferric citrate has been researched along with Chronic Kidney Diseases in 39 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 27 (69.23) | 24.3611 |
| 2020's | 12 (30.77) | 2.80 |
| Authors | Studies |
|---|---|
| Badve, SV; Block, GA; Elder, GJ; Hawley, CM; Johnson, DW; Lioufas, NM; Pascoe, EM; Toussaint, ND | 1 |
| Blydt-Hansen, TD; Denburg, MR; Dokras, A; Elashoff, DA; Greenbaum, LA; Guzman, GAL; Hanudel, MR; Hayde, NA; Imani, PD; Isakova, T; Kaskel, FJ; Kogon, AJ; Laster, ML; Mendley, SR; Mitsnefes, MM; Portale, AA; Quigley, RP; Ramirez, JA; Reyes, LZ; Salusky, IB; Srivaths, PR; Warady, BA; Weidemann, DK; Zaritsky, JJ | 1 |
| Hashimoto, T; Ito, K; Matsumoto, Y; Nishino, N; Okuda, Y; Susai, H; Yamada, R; Yokoyama, K | 1 |
| Chua, K; Czaya, B; Gabayan, V; Ganz, T; Hanudel, MR; Jung, G; Qiao, B; Wong, S | 1 |
| Allen, MR; Avin, KG; Biruete, A; Chen, NX; Clinkenbeard, EL; Metzger, CE; Moe, SM; O'Neill, K; Srinivasan, S; Stacy, AJ; Swallow, EA; Vrabec, C | 1 |
| Agoro, R; Allen, MR; Clinkenbeard, EL; Damrath, JG; Hum, JM; Liesen, MP; Ni, P; Noonan, ML; Swallow, EA; Wallace, JM; White, KE | 1 |
| Ito, K; Yokoyama, K | 1 |
| Berner, T; Dieguez, G; Ferro, C; Kovesdy, CP; Metz, S; Moore, J; Szabo, E | 1 |
| Ai, X; Chen, X; Dong, H; Feng, J; Huang, B; Huang, X; Li, J; Li, L; Li, X; Li, Y; Luo, H; Xiao, H; Xue, G; You, S; Zhang, Y | 1 |
| Fishbane, S; Ganz, T; Pergola, PE | 1 |
| Capella, M; Courbon, G; David, V; Dussold, C; Francis, C; Gerber, C; Isakova, T; Martin, A; Mehta, R; Neuburg, S; Qi, L; Wang, X; Wolf, M | 1 |
| Hanudel, MR | 1 |
| Choi, YJ; Noh, Y; Shin, S | 1 |
| Alikhani, L; Cogburn, K; Jing, W; Khazaeli, M; Lau, WL; Liu, H; Nunes, ACF; Said, H; Vaziri, ND; Zhao, Y | 1 |
| Belo, D; Crawford, P; Farag, YMK; Goldfarb-Rumyantzev, A; Luo, W; Moustafa, M; Pergola, PE | 1 |
| Del Vecchio, L; Locatelli, F | 1 |
| Iguchi, A; Kazama, JJ; Narita, I; Suzuki, Y; Tasaki, K; Yamamoto, S; Yamazaki, M | 1 |
| Block, GA; Chertow, GM; Fishbane, S; LeWinter, RD; Neylan, JF; Pergola, PE; Uhlig, K | 1 |
| Gales, B; Hanudel, MR; Laster, M; Ramos, G; Salusky, IB | 1 |
| Fishbane, S; McCullough, PA; Neylan, JF; Pergola, PE; Uhlig, K | 1 |
| Farzaneh, T; Jing, W; Khazaeli, M; Lau, WL; Nunes, ACF; Vaziri, ND | 1 |
| Comeau, AM; England, W; Khazaeli, M; Langille, MGI; Lau, WL; Nunes, ACF; Phan, J; Suematsu, Y; Vaziri, ND; Whiteson, K | 1 |
| Block, GA; Chertow, GM; Fishbane, S; LeWinter, RD; Martins, JG; Neylan, JF; Pergola, PE; Uhlig, K | 1 |
| Goto, M; Jing, W; Khazaeli, M; Lau, WL; Nunes, ACF; Suematsu, Y; Vaziri, ND | 1 |
| Bino, A; Ganz, T; Salusky, IB | 1 |
| Giri, K; Jain, D; Nand, N | 1 |
| Akiba, T; Block, GA; Fukagawa, M; Hirakata, H; Kumagai, Y; Nakayama, M; Sawada, K; Yokoyama, K | 1 |
| Block, GA; Chertow, GM; Fishbane, S; Pergola, PE; Rodriguez, M; Shemesh, S; Smits, G; Wolf, M | 1 |
| Iida, A; Maeda, K; Matsumoto, Y; Matsuo, A; Miyazaki, A; Nishino, N; Orui, S | 1 |
| Hasuike, Y; Kuragano, T; Nakanishi, T; Nanami, M; Yahiro, M | 1 |
| Lederer, SR; Schmid, H | 1 |
| Jang, SM; Pai, AB; Wegrzyn, N | 1 |
| Yokoyama, K | 1 |
| Ito, T; Iwashita, Y; Shigematsu, T | 1 |
| Locatelli, F; Mazzaferro, S; Yee, J | 1 |
| Vaziri, ND | 1 |
| Block, GA | 1 |
| Connelly, C; Dwyer, JP; Koury, MJ; Lewis, JB; Niecestro, R; Schulman, G; Sika, M; Umanath, K | 1 |
16 review(s) available for ferric citrate and Chronic Kidney Diseases
| Article | Year |
|---|---|
Systematic Review and Meta-Analyses of the Effects of Phosphate-Lowering Agents in Nondialysis CKD.
Topics: Chelating Agents; Ferric Compounds; Humans; Hyperphosphatemia; Lanthanum; Phosphates; Renal Insufficiency, Chronic; Sevelamer | 2022 |
A review of ferric citrate clinical studies, and the rationale and design of the Ferric Citrate and Chronic Kidney Disease in Children (FIT4KiD) trial.
Topics: Child; Ferric Compounds; Fibroblast Growth Factors; Humans; Iron; Minerals; Phosphates; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic | 2022 |
Comparative Efficacy and Acceptability of 12 Phosphorus-Lowering Drugs in Adults with Hyperphosphatemia and Chronic Kidney Disease: A Systematic Review and Network Meta-Analysis.
Topics: Adult; Humans; Hyperphosphatemia; Network Meta-Analysis; Renal Dialysis; Renal Insufficiency, Chronic | 2023 |
Novel Oral Iron Therapies for Iron Deficiency Anemia in Chronic Kidney Disease.
Topics: Administration, Oral; Anemia, Iron-Deficiency; Ferric Compounds; Hematinics; Humans; Pyrones; Renal Insufficiency, Chronic | 2019 |
Ferric citrate in the management of hyperphosphataemia and iron deficiency anaemia: A meta-analysis in patients with chronic kidney disease.
Topics: Anemia, Iron-Deficiency; Ferric Compounds; Humans; Hyperphosphatemia; Phosphates; Renal Insufficiency, Chronic | 2021 |
Iron-based phosphate binders: a paradigm shift in the treatment of hyperphosphatemic anemic CKD patients?
Topics: Anemia; Chelating Agents; Ferric Compounds; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperphosphatemia; Renal Insufficiency, Chronic | 2017 |
Mechanism of Action and Clinical Attributes of Auryxia
Topics: Administration, Intravenous; Anemia, Iron-Deficiency; Cardiovascular Diseases; Chelating Agents; Clinical Trials as Topic; Ferric Compounds; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperphosphatemia; Iron; Iron Overload; Phosphates; Renal Insufficiency, Chronic; Risk Factors; Treatment Outcome | 2019 |
[Pharmacological profile and clinical findings of a new phosphate binder, ferric citrate hydrate (Riona® Tablets)].
Topics: Animals; Chelating Agents; Clinical Trials as Topic; Ferric Compounds; Ferritins; Gastrointestinal Diseases; Humans; Hyperphosphatemia; Peritoneal Dialysis; Renal Dialysis; Renal Insufficiency, Chronic; Tablets | 2014 |
Novel iron-containing phosphate binders and anemia treatment in CKD: oral iron intake revisited.
Topics: Administration, Oral; Anemia; Animals; Ferric Compounds; Humans; Hyperphosphatemia; Phosphates; Renal Insufficiency, Chronic | 2016 |
Novel iron-containing phosphate binders for treatment of hyperphosphatemia.
Topics: Animals; Carbonates; Clinical Trials as Topic; Drug Combinations; Ferric Compounds; Humans; Hyperphosphatemia; Iron; Lanthanum; Magnesium; Phosphates; Renal Insufficiency, Chronic; Sevelamer; Starch; Sucrose | 2015 |
Iron-based phosphate binders--a new element in management of hyperphosphatemia.
Topics: Animals; Drug Combinations; Ferric Compounds; Humans; Hyperphosphatemia; Medication Adherence; Phosphates; Renal Insufficiency, Chronic; Sevelamer; Sucrose | 2016 |
[Phosphate metabolism and iron deficiency].
Topics: Biomarkers; Calcitriol; Familial Hypophosphatemic Rickets; Ferric Compounds; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Iron; Iron Deficiencies; Kidney; Mutation; Phosphates; Renal Insufficiency, Chronic | 2016 |
[Treatment for CKD-MBD(Chronic Kidney Disease-Mineral and Bone Disorder)].
Topics: Bone and Bones; Bone Diseases, Metabolic; Calcimimetic Agents; Calcinosis; Calcium Carbonate; Cardiovascular Diseases; Cinacalcet; Ferric Compounds; Fractures, Bone; Humans; Minerals; Parathyroidectomy; Phosphates; Phosphorus, Dietary; Renal Insufficiency, Chronic; Risk Factors; Sevelamer | 2016 |
Iron Therapy Challenges for the Treatment of Nondialysis CKD Patients.
Topics: Administration, Intravenous; Administration, Oral; Anemia; Ferric Compounds; Hematinics; Hemoglobins; Humans; Iron; Iron Compounds; Liposomes; Practice Guidelines as Topic; Renal Insufficiency, Chronic | 2016 |
Safety Issues in Iron Treatment in CKD.
Topics: Anemia, Iron-Deficiency; Cardiovascular Diseases; Cognitive Dysfunction; Diabetes Mellitus, Type 2; Disease Progression; Ferric Compounds; Hematinics; Humans; Iron Compounds; Iron Overload; Kidney Failure, Chronic; Oxidative Stress; Reactive Oxygen Species; Renal Dialysis; Renal Insufficiency, Chronic | 2016 |
Ferric Citrate in Patients With Chronic Kidney Disease.
Topics: Anemia, Iron-Deficiency; Ferric Compounds; Hematinics; Humans; Kidney Failure, Chronic; Renal Dialysis; Renal Insufficiency, Chronic | 2016 |
8 trial(s) available for ferric citrate and Chronic Kidney Diseases
| Article | Year |
|---|---|
Ferric Citrate Dosing in Iron Deficiency Anemia in Nondialysis-Dependent Chronic Kidney Disease.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Iron-Deficiency; Female; Ferric Compounds; Fibroblast Growth Factor-23; Glomerular Filtration Rate; Hemoglobins; Humans; Male; Middle Aged; Phosphates; Renal Insufficiency, Chronic; Time Factors | 2021 |
Effect of ferric citrate hydrate on FGF23 and PTH levels in patients with non-dialysis-dependent chronic kidney disease with normophosphatemia and iron deficiency.
Topics: Aged; Anemia, Iron-Deficiency; Female; Ferric Compounds; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Japan; Male; Middle Aged; Parathyroid Hormone; Renal Insufficiency, Chronic; Tokyo | 2018 |
Hemoglobin response to ferric citrate in patients with nondialysis-dependent chronic kidney disease and iron deficiency anemia.
Topics: Anemia, Iron-Deficiency; Ferric Compounds; Hemoglobins; Humans; Renal Insufficiency, Chronic | 2018 |
Usefulness of Oral Ferric Citrate in Patients With Iron-Deficiency Anemia and Chronic Kidney Disease With or Without Heart Failure.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anemia, Iron-Deficiency; Biomarkers; Dose-Response Relationship, Drug; Double-Blind Method; Female; Ferric Compounds; Ferritins; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Renal Insufficiency, Chronic; Treatment Outcome; Young Adult | 2018 |
Effect of ferric citrate on serum phosphate and fibroblast growth factor 23 among patients with nondialysis-dependent chronic kidney disease: path analyses.
Topics: Aged; Anemia, Iron-Deficiency; Biomarkers; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Female; Ferric Compounds; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Follow-Up Studies; Humans; Male; Phosphates; Renal Dialysis; Renal Insufficiency, Chronic | 2019 |
Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD.
Topics: Aged; Biomarkers; Chelating Agents; Double-Blind Method; Female; Ferric Compounds; Ferritins; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperphosphatemia; Iron; Japan; Male; Middle Aged; Phosphates; Renal Insufficiency, Chronic; Time Factors; Transferrin; Treatment Outcome | 2014 |
A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3-5.
Topics: Aged; Anemia, Iron-Deficiency; Disease Progression; Double-Blind Method; Female; Ferric Compounds; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Hematinics; Humans; Male; Middle Aged; Phosphates; Renal Insufficiency, Chronic | 2015 |
Rationale and study design of a three-period, 58-week trial of ferric citrate as a phosphate binder in patients with ESRD on dialysis.
Topics: Adolescent; Adult; Chelating Agents; Female; Ferric Compounds; Humans; Kidney Failure, Chronic; Male; Phosphates; Renal Dialysis; Renal Insufficiency, Chronic; Young Adult | 2013 |
15 other study(ies) available for ferric citrate and Chronic Kidney Diseases
| Article | Year |
|---|---|
Safety and effectiveness of ferric citrate hydrate in serum phosphorus management of patients with chronic kidney disease: a long-term, real-world, observational, post-marketing surveillance study.
Topics: Ferric Compounds; Ferritins; Humans; Hyperphosphatemia; Iron; Phosphorus; Product Surveillance, Postmarketing; Prospective Studies; Renal Dialysis; Renal Insufficiency, Chronic | 2022 |
Renoprotective effects of ferric citrate in a mouse model of chronic kidney disease.
Topics: Animals; Disease Models, Animal; Female; Ferric Compounds; Humans; Inflammation; Iron; Male; Mice; Mice, Knockout; Phosphates; Renal Insufficiency, Chronic | 2022 |
Effects of ferric citrate and intravenous iron sucrose on markers of mineral, bone, and iron homeostasis in a rat model of CKD-MBD.
Topics: Animals; Biomarkers; Chronic Kidney Disease-Mineral and Bone Disorder; Ferric Compounds; Ferric Oxide, Saccharated; Fibroblast Growth Factors; Homeostasis; Iron; Male; Minerals; Parathyroid Hormone; Phosphorus; Rats; Renal Insufficiency, Chronic; Transferrins | 2022 |
Segregating the effects of ferric citrate-mediated iron utilization and FGF23 in a mouse model of CKD.
Topics: Animals; Citric Acid; Disease Models, Animal; Electrolytes; Ferric Compounds; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Iron; Mice; Minerals; Renal Insufficiency, Chronic; RNA, Messenger | 2022 |
Iron absorption and phosphate-lowering effects of ferric citrate hydrate are not influenced by gastric acid secretion inhibitors in patients with chronic kidney disease: a retrospective post hoc analysis.
Topics: Ferritins; Gastric Acid; Humans; Iron; Phosphates; Renal Dialysis; Renal Insufficiency, Chronic; Retrospective Studies | 2023 |
Real-World Phosphate Binder Use among Dialysis-Dependent Patients with CKD.
Topics: Aged; Chelating Agents; Ferric Compounds; Humans; Hyperphosphatemia; Medicare; Phosphates; Renal Dialysis; Renal Insufficiency, Chronic; Sevelamer; United States | 2023 |
Ferric citrate reduces fibroblast growth factor 23 levels and improves renal and cardiac function in a mouse model of chronic kidney disease.
Topics: Animals; Autoantigens; Collagen Type IV; Disease Models, Animal; Drug Evaluation, Preclinical; Ferric Compounds; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Heart; Kidney; Mice; Mice, Knockout; Renal Insufficiency, Chronic | 2019 |
Ferric citrate: cardio- and renoprotective in chronic kidney disease?
Topics: Anemia, Iron-Deficiency; Animals; Ferric Compounds; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Mice; Renal Insufficiency, Chronic | 2019 |
Route of intestinal absorption and tissue distribution of iron contained in the novel phosphate binder ferric citrate.
Topics: Animals; Colon; Erythropoietin; Ferric Compounds; Hyperphosphatemia; Intestinal Absorption; Iron; Male; Phosphates; Rats; Rats, Sprague-Dawley; Renal Insufficiency, Chronic; Tissue Distribution | 2020 |
Clinical experience with the use of ferric citrate as a phosphate binder in pediatric dialysis patients.
Topics: Adolescent; Anemia, Iron-Deficiency; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; Ferric Compounds; Humans; Hyperphosphatemia; Male; Off-Label Use; Phosphates; Renal Dialysis; Renal Insufficiency, Chronic; Retrospective Studies; Treatment Outcome | 2018 |
Phosphate Binder, Ferric Citrate, Attenuates Anemia, Renal Dysfunction, Oxidative Stress, Inflammation, and Fibrosis in 5/6 Nephrectomized CKD Rats.
Topics: Anemia; Animals; Colon; Down-Regulation; Epithelial Cells; Ferric Compounds; Fibrosis; Inflammation; Iron; Kidney Tubules, Proximal; Male; Nephrectomy; NF-E2-Related Factor 2; Oxidative Stress; Phosphates; Rats; Rats, Sprague-Dawley; Renal Insufficiency, Chronic; Tight Junction Proteins; Up-Regulation; Zonula Occludens-1 Protein | 2018 |
The Phosphate Binder Ferric Citrate Alters the Gut Microbiome in Rats with Chronic Kidney Disease.
Topics: Animals; Blood Pressure; Cecum; DNA, Bacterial; Feces; Ferric Compounds; Gastrointestinal Microbiome; Kidney; Male; Phosphates; Rats; Rats, Sprague-Dawley; Renal Insufficiency, Chronic; RNA, Ribosomal, 16S | 2018 |
Ferric Citrate Attenuates Cardiac Hypertrophy and Fibrosis in a Rat Model of Chronic Kidney Disease.
Topics: Animals; Biomarkers; Cardiomegaly; Ferric Compounds; Fibrosis; Iron; Male; Natriuretic Peptide, Brain; Peptide Fragments; Phosphates; Random Allocation; Rats; Rats, Sprague-Dawley; Renal Insufficiency, Chronic | 2019 |
Role of Ferric Citrate in Hyperphosphatemia and Iron Deficiency Anemia in Non Dialysis CKD Patients.
Topics: Adult; Anemia, Iron-Deficiency; Ferric Compounds; Humans; Hyperphosphatemia; India; Prospective Studies; Renal Dialysis; Renal Insufficiency, Chronic | 2019 |
Ferric citrate (Auryxia) for hyperphosphatemia.
Topics: Drug Interactions; Ferric Compounds; Humans; Hyperphosphatemia; Renal Dialysis; Renal Insufficiency, Chronic | 2015 |